March 5, 2024 7:37am
After Monday’s market dive; the Dow moved down 0.25%, the S&P 500 slipped 0.1% and the Nasdaq dropped 0.4% while the cell, and gene therapy sector closed negative with 10 incliners, 24 decliners and 1 flat
News: Regenxbio (RGNX +$5.53) reported additional interim safety and efficacy data in the P1/2 AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old, including RGX-202 microdystrophin expression from dose level 2 and video of trial clinic assessments demonstrating initial evidence of strength and functional improvement.
Earnings: AxoGen (AXGN)
Pre-open Indications: 4 Negative and 1 Positive Indications
Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone and new website!
Never leave an investor uninformed!
Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi provides the extenuating factors of share pricing.
Tuesday: The pre-open Dow futures are DOWN -0.12% or ( -46 points), the S&P futures are DOWN -0.24% or (-12 points) as the Nasdaq futures are DOWN -0.54% or ( -98 points)
U.S. stock futures inched lower Tuesday,
European markets were lower,
Most Asia Pacific markets were lower
Henry’omics:
We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …
US stocks closed lower on Monday as investors girded for a week where Federal Reserve Chair Jerome Powell's testimony and the monthly jobs report could put equity gains to the test.
- The Dow closed DOWN -97.55 points or -0.25%, the S&P closed DOWN -=6.13 points -0.12% while the Nasdaq closed DOWN -67.43 points or -0.41%
Economic Data Docket: S&P Global US Services purchasing managers’ index, durable goods orders and ISM Services Index
Monday’s night RegMed Investors (RMi) Closing Bell: “casting into the portfolio sea, maybe it was the barb’s hook failing from the equity’s opening. As there was no bait on the portfolio hook today” … https://www.regmedinvestors.com/articles/13355
Q1/24: march – 1 positive and 1 negative closes
- February – 1 market holiday, 11 positive and 9 negative closes
- January: 2 holidays, 11 negative and 8 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context:
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Positive Indications:
Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Regenxbio (RGNX) closed up +$0.17 with a positive +$5.53 pre-open indication after reporting additional interim safety and efficacy data in the P1/2 AFFINITY DUCHENNE® trial of RGX-202 in patients with Duchenne muscular dystrophy (Duchenne) ages 4 to11 years old, including RGX-202 microdystrophin expression from dose level 2 and video of trial clinic assessments demonstrating initial evidence of strength and functional improvement.
Negative Indications:
Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
BioLife Solutions (BLFS) closed up +$0.18 after Friday’s +$1.07, Thursday’s -$0.20 with a negative -$0.47 or -2.59% pre-open indication
CRISPR Therapeutics (CRSP) closed down -$2.01 after Friday’s -$0.47, Thursday’s -$3.46, Wednesday’s -$1.44 and last Tuesday’s +$3.06 with a negative -$0.74 or -0.91% pre-open indication.
Voyager Therapeutics (VYGR) closed up +$0.20 after Friday’s +$1.12 with a negative -$0.35 or -3.63% pre-open indication
Blueprint Medicine (BPMC) closed down -$4.32 after Friday’s +$1.60, Thursday’s -$1.93, Wednesday’s -$4.34, Tuesday’s +$4.74 and last Monday’s +$5.56 with a negative -$0.01 or -0.01% pre-open indication.
The BOTTOM LINE:
The cell and gene therapy sector equities dived on Monday after Friday’s pop after Thursday’s dive after Wednesday decent following Tuesday positive close following last Monday.
- The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.
19 (of 35 covered companies) have reported … RegMed Investors (RMi) Research Note: Q4/23 earnings reporting dates, net losses, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/13166
I reiterate, “Don't chase the cell and gene therapy sector.”
Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!
<span style="font-family:"rom Friday" s="" market:",serif'="">
<span style="font-family:"rom Friday" s="" market:",serif'="">From Monday’s market: stocks closed lower on Monday, backing away from record highs…
- the 10-year U.S. Treasury yield rose to 4.21%
Welcome to my world of defining the “grey’ in our universe!
- Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
